Royal Manchester Children’s Hospital
We are delighted to invite applications for a consultant in paediatric gastroenterology to join our fantastic and dynamic team of consultant gastroenterologists. We provide paediatric gastroenterology service across the Northwest of England and welcome applications from highly motivated candidates with or without a special interest.
There are currently 4 Consultants and with the new posts there will be 6 Consultants. There are 5 IBD and Nutrition Specialist Nurses based at RMCH, alongside a Gastro Specialist Nurse for pH and impedance test and Oesophageal /Ano-rectal Manometry. The team undertake a weekly Intestinal Failure and PN MDT, Weekly IBD MDT Meetings, 2 Grand Round MDT meetings per week and a weekly Histology with one of the meeting dedicated to IBD/Radiology/Histopathology MDT meeting. There are 6.5 Consultant Gastroenterology outpatient clinics per week with the IBD and Nutrition Specialist nurses undertaking weekly outpatient clinics as well.
One post will be Consultant will substantive and the second will be locum post for 12 months with a view of this becoming substantive after. Posts holders are welcome to develop their special interests; however both post holders will do some general gastroenterology as well.
The Gastroenterology Department works closely with all tertiary specialities based at RMCH and provides support to District General Hospitals across the Greater Manchester conurbation and beyond. Joint outpatient clinics are held with the Endocrinology, Surgery, Immunology/Early onset IBD, and Pancreatic with adult gastroenterologist and Allergy teams with a Transition clinic occurring every 3 months. There is also joint clinic for post small bowel and liver transplant patients with Birmingham.
Each Gastroenterology Consultant has one elective Endoscopy list per week in the theatre suites. Emergency theatre sessions for urgent cases are also available. Emergency and out of hours cover is provided by a Consultant on call rota (non- resident) which is high intensity. The on call consultant undertakes ward rounds on Saturdays and Sundays.
Further information can be obtained from
Dr. Andrew Fagbemi, Clinical Lead on 0161 701 2371 firstname.lastname@example.org.
Dr Loveday Jago. 0161 7015566 LovedayJane.Jago@mft.nhs.uk
Dr Mars Skae, CSU Clinical Director on 0161 701 0650 email@example.com
Application through www.careers.cmft.nhs.uk
CLOSING DATE OF 28th May 2021.
Interview Date: June/July 2021.
Covid19 Vaccination update 7th April 2021
(replaces advice on BSPGHAN website on 31st January 2021)
Today, April 7th, 2021, the Joint Committee on Vaccination and Immunisation (JCVI) has changed their clinical advice on Covid 19 vaccines for those aged under 30 years.
Adults aged 18 to 29 who do not have an underlying health condition that puts them at greater risk from Covid should be offered an alternative to the Astra Zeneca vaccine if one is available.
The MHRA advised that-
- side-effects were “extremely rare” – and more work was going on to identify if the Astra Zeneca vaccine was causing blood clots.
- People who have had their first dose of the AstraZeneca vaccine should still get their second dose.
- Only those who suffered one of these rare blood clots after the first dose should not get vaccinated.
- People with blood disorders that leave them at risk of clotting should discuss the benefits and risks of vaccination with their doctor.
- The JCVI today said that they have not made a decision yet (on vaccine advice) on those aged under 18 years.
The Pfizer/BioNTech vaccine is authorised for use in individuals aged 16 years and over, and the Oxford/AstraZeneca vaccine is authorised for individuals aged 18 years and over.
Also see that here that the RCPCH updated their advice on 29th March 2021, for paediatricians on children and young people and the COVID-19 vaccination programme https://www.rcpch.ac.uk/news-events/news/message-paediatricians-children-young-people-covid-19-vaccination-programme
This advice may be updated in light of the announcement today.
We are now in the first phase of the programme during which young people (aged 16 years and over) with specific clinical vulnerabilities will be offered vaccination.1 ( Based on JCVI advice, individuals aged 16–65 years in at-risk groups are eligible for immunisation in Phase 1 of the programme).
The Green Book says: “Children and young people have a very low risk of COVID-19, severe disease or death due to SARS-CoV-2 compared to adults and so COVID-19 vaccines are not routinely recommended for children and young people under 16 years of age. Children under 16 year of age, even if they are CEV, are at low risk of serious morbidity and mortality, and, given the absence of safety and efficacy data on the vaccine, are not recommended for vaccination.” 2
While this is the case, vaccinations should not be offered to children and young people who fall outside the categories advised by the JCVI and the Green Book.
The only other group identified by the Joint Committee on Vaccination and Immunisation (JCVI) and the Green Book3 that may be considered for the vaccine during phase 1 are:
- older children (aged 12 years and over) with severe neuro-disabilities and recurrent respiratory tract infections who frequently spend time in specialised residential care settings for children with complex needs.
Such vaccinations would be considered unlicensed use.4 Paediatricians should discuss the benefits and risks and limited safety data with children, young people and their parents/guardians. Any vaccination would need to be authorised by a prescriber (usually a doctor). We would expect that this discussion would take into account:
- the frequency and severity of respiratory infection, and
- the history of hospital admissions, particularly the risk of or previous admissions to paediatric intensive care due to respiratory tract infections.
It is important to stress that at this time the JCVI consider that there are no data to support use of the vaccine in younger age groups or other clinical groups.
BSPGHAN President April 7th 2021